Mozafancogene autotemcel
Gene therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 11, 2019 (NCT03814408)
Timeline
Indications
Studied for
Mechanism of action
- DNA repair protein RAD51 homolog 1Supplementation
RAD51 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802257 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04248439 | Phase 2 | Feb 29, 2020 | Rocket Pharma Limited, Stanford University |
| NCT04069533 | Phase 2 | Aug 31, 2019 | Hospital Infantil Universitario Niño Jesús, Madrid, Spain, Rocket Pharma Limited |
| NCT03814408 | Phase 1 | Jan 11, 2019 | Rocket Pharma Limited, Stanford University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rocket Pharma Limited | For profit | 3 | 3 | 2 | 2019 |
| Stanford University | Academic/Hospital | 2 | 0 | 2 | 2019 |
| Hospital Infantil Universitario Niño Jesús, Madrid, Spain | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1